Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ID: DRG0CIZWI)
ADC Name
AMT-676
Synonyms
AMT-676a; AMT-676a ADC; AMT-676
   Click to Show/Hide
Organization
Multitude Therapeutics (Originator)
Drug Status
Phase 2
Drug-to-Antibody Ratio
4
Structure
Antibody Name
Anti-CDH17 antibody
  Antibody Info 
Antigen Name
Cadherin-17 (CDH17)
  Antigen Info 
Payload Name
Exatecan
  Payload Info 
Payload Target
DNA topoisomerase 1 (TOP1)
  Target Info 
Linker Name
T1000
  Linker Info 
Conjugate Type
Random Cysteines
Combination Type
sesutecan
2027 Update
The disease landscape of This ADC
2027 Update
The clinical trial pipelines of This ADC
Disease Name Phase 1 Phase 2 Phase 3 Approved
Unspecific solid tumor
1 Trials
Clinical trial identifier
NCT06400485; CTR20243449
General Information of The Activity Data Related to This ADC
Identified from the Human Clinical Data
Click To Hide/Show 1 Activity Data Related to This Level
Standard Type NCT Number Clinical Status Clinical Trial Description
Undisclosed  NCT06400485
EARLY_PHASE1
First-in-Human, Phase 1 Study of AMT-676 in Patients With Advanced Solid Tumors
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Patients Enrolled
Eligible patients must have unresectable advanced solid tumors (e.g., colorectal, gastric, or pancreatic cancers), ECOG 0-1, and adequate organ function. Key exclusions include prior ADC/targeted therapy, CNS metastasis, active infections, severe cardiac/respiratory conditions, recent major surgery/radiation, pregnancy, or concurrent investigational treatment.

   Click to Show/Hide
Administration Dosage
Participants will receive AMT-676 administered intravenously. Participants will be observed for first instance of dose limiting toxicities (DLT).
Related Clinical Trial
NCT Number NCT06400485  Clinical Status EARLY_PHASE1
Clinical Description First-in-Human, Phase 1 Study of AMT-676 in Patients With Advanced Solid Tumors
Primary Endpoint
The study focuses on determining the Recommended Phase 2 Dose (RP2D) and Maximum Tolerated Dose (MTD) based on dose-limiting toxicities (DLTs) and safety profiles, with assessments within 30 days post-dosing. Adverse events will also be evaluated using CTCAE v5.0 for severity and incidence.
Other Endpoint
Pharmacokinetic parameters such as Cmax, Tmax, AUC, and t1/2 of AMT-676 will be measured within 30 days post-dosing. Immunogenicity will be assessed via anti-drug antibody (ADA) levels, while efficacy endpoints include ORR (CR/PR), DCR (CR/PR/SD), and PFS per RECIST v1.1.
References
Ref 1 AMT-676 in Patients With Advanced Solid Tumors